On April 18, 2011 was the Annual General Meeting of Moberg Derma AB (publ). In all suggestions the meeting decided in accordance with the proposal.

The meeting decided that as a new member elects Peter Rothschild.

After the annual general meeting, the board has the following composition:

•                            Mats Pettersson (Chairman)
•                            Wenche Rolfsen (Vice Chairman)
•                            Bertil Karlmark
•                            Torbjörn Koivisto
•                            Gustaf Lindewald
•                            Peter Wolpert
•                            Peter Rothschild

Mr Rothschild has extensive experience in health care and biotechnology. He is CEO and founder of BioGaia AB (publ). Peter Rothschild is also chairman of the Loft Industries AB and board member of several of BioGaia subsidiaries. Peter Rothschild has also been a member of Diamyd Medical AB and Perlan AB.

For further information, please contact:
Peter Wolpert, President and CEO of Moberg Derma
Telephone: +46 8 522 307 00
Mobile: +46 735 71 35

About Moberg Derma
Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company’s products are based on proven compounds, which reduce time to market, development costs and risk. The portfolio covers projects in the preclinical phase to approved and launched products. The company began operations at the Karolinska Institute in Stockholm in 2006. Moberg Derma is owned by institutional and private investors, Board and management. For further information, please visit:


About Us

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The ompany’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, NewSkin®, Dermoplast®, Domeboro®. Kerasal Nail® (Emtrix® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).For further information, please visit:



Documents & Links